Cargando…

Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma

Pancreatic cancer is a highly lethal malignancy. Developments in recent years have broadened our therapeutic armamentarium. Novel drugs such as nab‐paclitaxel, liposomal irinotecan and chemotherapy regimens such as FOLFIRINOX have been successfully tested in clinical trials. Data on patients outside...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegewisch‐Becker, Susanna, Aldaoud, Ali, Wolf, Thomas, Krammer‐Steiner, Beate, Linde, Hartmut, Scheiner‐Sparna, Renate, Hamm, David, Jänicke, Martina, Marschner, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585733/
https://www.ncbi.nlm.nih.gov/pubmed/30006989
http://dx.doi.org/10.1002/ijc.31751
_version_ 1783428761497108480
author Hegewisch‐Becker, Susanna
Aldaoud, Ali
Wolf, Thomas
Krammer‐Steiner, Beate
Linde, Hartmut
Scheiner‐Sparna, Renate
Hamm, David
Jänicke, Martina
Marschner, Norbert
author_facet Hegewisch‐Becker, Susanna
Aldaoud, Ali
Wolf, Thomas
Krammer‐Steiner, Beate
Linde, Hartmut
Scheiner‐Sparna, Renate
Hamm, David
Jänicke, Martina
Marschner, Norbert
author_sort Hegewisch‐Becker, Susanna
collection PubMed
description Pancreatic cancer is a highly lethal malignancy. Developments in recent years have broadened our therapeutic armamentarium. Novel drugs such as nab‐paclitaxel, liposomal irinotecan and chemotherapy regimens such as FOLFIRINOX have been successfully tested in clinical trials. Data on patients outside of clinical trials are scarce but necessary to assess and improve the standard of care. We present data on treatment and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Between February 2014 and June 2017, patients were recruited by 104 sites at start of first‐line therapy into the ongoing, prospective clinical cohort study TPK (Tumour Registry Pancreatic Cancer). As first‐line therapy, 89% of patients received one of the three treatment regimens: gemcitabine monotherapy (23%), nab‐paclitaxel plus gemcitabine (42%), or FOLFIRINOX (24%). The corresponding subgroups differed: Patients receiving gemcitabine monotherapy were older and more comorbid (median age 78 years, 73% ECOG ≥ 1) than patients receiving nab‐paclitaxel plus gemcitabine (median age 71, 64% ECOG ≥ 1) or patients receiving FOLFIRINOX (median age 60, 52% ECOG ≥ 1). At least 40% of patients died before receiving second‐line treatment. First‐line progression‐free survival was 4.6 months (95% CI: 3.7–5.2) for gemcitabine, 5.6 months (95% CI: 5.0–6.2) for nab‐paclitaxel plus gemcitabine, and 6.3 months (95% CI: 5.5–6.9) for FOLFIRINOX. Our data represent the treatment reality in a German community setting. Although there are no stringent inclusion criteria for our cohort study, overall survival is comparable to that reported by randomised clinical trials.
format Online
Article
Text
id pubmed-6585733
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-65857332019-06-27 Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma Hegewisch‐Becker, Susanna Aldaoud, Ali Wolf, Thomas Krammer‐Steiner, Beate Linde, Hartmut Scheiner‐Sparna, Renate Hamm, David Jänicke, Martina Marschner, Norbert Int J Cancer Cancer Epidemiology Pancreatic cancer is a highly lethal malignancy. Developments in recent years have broadened our therapeutic armamentarium. Novel drugs such as nab‐paclitaxel, liposomal irinotecan and chemotherapy regimens such as FOLFIRINOX have been successfully tested in clinical trials. Data on patients outside of clinical trials are scarce but necessary to assess and improve the standard of care. We present data on treatment and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Between February 2014 and June 2017, patients were recruited by 104 sites at start of first‐line therapy into the ongoing, prospective clinical cohort study TPK (Tumour Registry Pancreatic Cancer). As first‐line therapy, 89% of patients received one of the three treatment regimens: gemcitabine monotherapy (23%), nab‐paclitaxel plus gemcitabine (42%), or FOLFIRINOX (24%). The corresponding subgroups differed: Patients receiving gemcitabine monotherapy were older and more comorbid (median age 78 years, 73% ECOG ≥ 1) than patients receiving nab‐paclitaxel plus gemcitabine (median age 71, 64% ECOG ≥ 1) or patients receiving FOLFIRINOX (median age 60, 52% ECOG ≥ 1). At least 40% of patients died before receiving second‐line treatment. First‐line progression‐free survival was 4.6 months (95% CI: 3.7–5.2) for gemcitabine, 5.6 months (95% CI: 5.0–6.2) for nab‐paclitaxel plus gemcitabine, and 6.3 months (95% CI: 5.5–6.9) for FOLFIRINOX. Our data represent the treatment reality in a German community setting. Although there are no stringent inclusion criteria for our cohort study, overall survival is comparable to that reported by randomised clinical trials. John Wiley & Sons, Inc. 2018-10-03 2019-03-01 /pmc/articles/PMC6585733/ /pubmed/30006989 http://dx.doi.org/10.1002/ijc.31751 Text en © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Cancer Epidemiology
Hegewisch‐Becker, Susanna
Aldaoud, Ali
Wolf, Thomas
Krammer‐Steiner, Beate
Linde, Hartmut
Scheiner‐Sparna, Renate
Hamm, David
Jänicke, Martina
Marschner, Norbert
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
title Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
title_full Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
title_fullStr Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
title_full_unstemmed Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
title_short Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
title_sort results from the prospective german tpk clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
topic Cancer Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585733/
https://www.ncbi.nlm.nih.gov/pubmed/30006989
http://dx.doi.org/10.1002/ijc.31751
work_keys_str_mv AT hegewischbeckersusanna resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT aldaoudali resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT wolfthomas resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT krammersteinerbeate resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT lindehartmut resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT scheinersparnarenate resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT hammdavid resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT janickemartina resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT marschnernorbert resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma
AT resultsfromtheprospectivegermantpkclinicalcohortstudytreatmentalgorithmsandsurvivalof1174patientswithlocallyadvancedinoperableormetastaticpancreaticductaladenocarcinoma